A hypothetical risk-sharing payment arrangement for Novartis AG’s new heart failure drug Entresto (valsartan/sacubitril) could effectively reduce the drug’s list price by 8.6%, according to a draft cost effectiveness report released by the Institute for Clinical and Economic Review Sept. 11.
The report considers the risk-sharing payment model along with an analysis of the long-term cost effectiveness of Entresto and its potential impact on US health care spending. It also addresses St. Jude Medical Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?